137813-36-6 Usage
Description
CYCLO(-ARG-ALA-ASP-D-PHE-VAL) is a cyclic peptide composed of the amino acid sequence arginine-alanine-aspartic acid-D-phenylalanine-valine. This peptide has garnered interest for its potential therapeutic applications, particularly in drug design and development. The cyclic structure of CYCLO(-ARG-ALA-ASP-D-PHE-VAL) is believed to enhance its stability and bioavailability, making it a promising candidate for pharmaceutical use. Ongoing research is exploring its biological activity and medicinal properties, with a focus on its ability to target specific cellular receptors or pathways for the treatment of various diseases and disorders.
Uses
Used in Pharmaceutical Industry:
CYCLO(-ARG-ALA-ASP-D-PHE-VAL) is used as a potential therapeutic agent for its increased stability and bioavailability compared to linear peptides. Its unique cyclic structure allows for targeted interactions with specific cellular receptors or pathways, offering a promising avenue for the development of new drugs to treat a range of diseases and disorders.
Used in Drug Design and Development:
CYCLO(-ARG-ALA-ASP-D-PHE-VAL) serves as a valuable component in the design and development of novel pharmaceuticals. Its cyclic nature may enhance the peptide's resistance to degradation and improve its ability to cross biological barriers, which is crucial for the effectiveness of drug delivery. Ongoing research aims to harness these properties to create more potent and selective medications.
Check Digit Verification of cas no
The CAS Registry Mumber 137813-36-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,7,8,1 and 3 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 137813-36:
(8*1)+(7*3)+(6*7)+(5*8)+(4*1)+(3*3)+(2*3)+(1*6)=136
136 % 10 = 6
So 137813-36-6 is a valid CAS Registry Number.
137813-36-6Relevant articles and documents
METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF ALPHA v BETA 5 MEDIATED ANGIOGENESIS
-
Page/Page column 16, (2008/06/13)
The present invention describes methods for inhibiting angiogenesis in tissues using vitronectin alpha v beta 5 antagonists. The alpha v beta 5-mediated angiogenesis is correlated with exposure to cytokines including vascular endothelial growth factor, transforming growth factor- alpha and epidermal growth factor. Inhibition of alpha v beta 5-mediated angiogenesis is particularly preferred in vascular endothelial ocular neovascular diseases, in tumor growth and in inflammatory conditions, using therapeutic compositions containing alpha v beta 5 antagonists.